Paris, France - June 13, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it was granted the award for "Leading Pan-European Quoted Company for Investor Relations" in the 2012 Thomson Reuters Extel Survey. Considered the leading benchmark for excellence in Investor Relations (IR), the survey highlights achievement across companies listed in Europe.
For the third year in a row, Sanofi was also voted first in the European Pharmaceuticals & Biotechnology sector and first among CAC 40 companies. In the 2009 Extel Survey, Sanofi was included for the first time in the list of Top 100 Pan-European Quoted Companies for IR, ranking in 35th place. In 2010, Sanofi finished in the 5th place and last year, the company was ranked 2nd.
"Investor Relations is a strategic management responsibility which ultimately contributes to a company's enhanced stock value in the long term. As the Extel IR rankings now get votes for over 1,500 quoted companies, to be first in Pan-Europe is a true accolade and recognition from investors and analysts," commented Steve Kelly, Managing Director, Extel with Thomson Reuters.
The 2012 Extel Survey reflects the contribution of over 14,000 professionals from over 2,100 buyside firms, more than 2,500 analysts from 270 brokerage firms/research houses and nearly 800 of Europe's largest quoted companies worldwide. All data, votes received and methodology applied were independently checked and verified by Deloitte. The results of the 39th annual Thomson Reuters Extel Survey were released on June 12, 2012 at a ceremony in London's Guildhall attended by Christopher A. Viehbacher, Chief Executive Officer, Sanofi, and Sébastien Martel, Vice President, Head of Investor Relations, Sanofi.
"This Extel award is a fantastic achievement for Sanofi and reflects the considerable efforts by management and the Investor Relations team to actively engage with the financial community. We thank investors and analysts for their votes," declared Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "Our award recognizes the high-quality dialogue between the company and the financial community and underscores Sanofi's commitment to excellence in Investor Relations."
To view the multimedia press release with a short video about these Extel Awards please click here
About the Thomson Reuters Extel Survey
Considered the leading benchmark for excellence in investment banking, asset management and investor relations, the 2012 Thomson Reuters Extel Survey highlights achievement across the buyside, sellside and corporate communities. The Survey ran from 19 March to 4 May 2012 and voting was primarily conducted online. The Survey reflects the contribution of over 14,000 professionals from over 2,100 buyside firms, more than 2,500 analysts from 270 brokerage firms/research houses and nearly 800 of Europe's largest quoted companies worldwide. All data, votes received and methodology applied were independently checked and verified by Deloitte. http://www.extelsurveys.com/
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|Media Relations||Investor Relations|
|Jean-Marc Podvin||Sébastien Martel|
|Tél. : + (33) 1 53 77 46 46||Tél. : + (33) 1 53 77 45 45|
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: SANOFI via Thomson Reuters ONE